Trial · NCT02720081
Outcomes26
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 20 of 26
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Baseline Pre-dose Forced Expiratory Volume in One Second (FEV1) | Before the first dose of study investigational product (Baseline) | Analysis population consists of randomized participants who received at least 1 dose of study drug. | Liter | MEAN |
| SECONDARY | Percentage of Days With Worsening Asthma Average Over Weeks 3 to 6 | Up to 4 weeks | Analysis population consists of randomized participants who received at least 1 dose of study drug and had at least 80% of days with a complete diary during Weeks 3 to 6 (a diary is considered complete if none of the 6 components used to determine asthma worsening are missing). | Percentage of days | LEAST_SQUARES_MEAN |
| SECONDARY | Percentage of Participants Who Experienced an Adverse Event (AE) | Up to 8 weeks | Analysis population included all randomized participants who received at least 1 dose of study drug. | Percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants Who Discontinued Study Drug Due to an AE | Up to 6 weeks | Analysis population included all randomized participants who received at least 1 dose of study drug. | Percentage of participants | NUMBER |
| SECONDARY | Change From Baseline in Alkaline Phosphatase (ALP) at Week 6 | Baseline and Week 6 | Analysis population includes all participants who received at least 1 dose of study drug and had non-missing change from baseline value at Week 6 for the analysis endpoint, ALP. | IU/L | MEAN |
| SECONDARY | Change From Baseline in Alanine Aminotransferase (ALT) at Week 6 | Baseline and Week 6 | Analysis population includes all participants who received at least 1 dose of study drug and had non-missing change from baseline value at Week 6 for the analysis endpoint, ALT. | IU/L | MEAN |
| SECONDARY | Change From Baseline in Aspartate Aminotransferase (AST) at Week 6 | Baseline and Week 6 | Analysis population includes all participants who received at least 1 dose of study drug and had non-missing change from baseline value at Week 6 for the analysis endpoint, AST. | IU/L | MEAN |
| SECONDARY | Change From Baseline in Bilirubin at Week 6 | Baseline and Week 6 | Analysis population includes all participants who received at least 1 dose of study drug and had non-missing change from baseline value at Week 6 for the analysis endpoint, bilirubin. | mg/dL | MEAN |
| SECONDARY | Change From Baseline in Eosinophil (Percent [%]) at Week 6 | Baseline and Week 6 | Analysis population includes all participants who received at least 1 dose of study drug and had non-missing change from baseline value at Week 6 for the analysis endpoint, eosinophil (%). | Percent of White Blood Cells | MEAN |
| SECONDARY | Change From Baseline in Neutrophil (%) at Week 6 | Baseline and Week 6 | Analysis population includes all participants who received at least 1 dose of study drug and had non-missing change from baseline value at Week 6 for the analysis endpoint, neutrophil (%). | Percent of White Blood Cells | MEAN |
| SECONDARY | Change From Baseline in Platelet Count at Week 6 | Baseline and Week 6 | Analysis population includes all participants who received at least 1 dose of study drug and had non-missing change from baseline value at Week 6 for the analysis endpoint, platelet count. | 10^9 cells/L | MEAN |
| SECONDARY | Change From Baseline in White Blood Cell Count at Week 6 | Baseline and Week 6 | Analysis population includes all participants who received at least 1 dose of study drug and had non-missing change from baseline value at Week 6 for the analysis endpoint, white blood cell count. | 10^9 cells/L | MEAN |
| SECONDARY | Change From Baseline in Hematocrit (%) at Week 6 | Baseline and Week 6 | Analysis population includes all participants who received at least 1 dose of study drug and had non-missing change from baseline value at Week 6 for the analysis endpoint, hematocrit (%). | Percent | MEAN |
| SECONDARY | Change From Baseline in Systolic Blood Pressure at Week 2 | Baseline and Week 2 | Analysis population includes all participants who received at least 1 dose of study drug and had non-missing change from baseline value at Week 2 for the analysis endpoint, systolic blood pressure. | mmHg | MEAN |
| SECONDARY | Change From Baseline in Systolic Blood Pressure at Week 4 | Baseline and Week 4 | Analysis population includes all participants who received at least 1 dose of study drug and had non-missing change from baseline value at Week 4 for the analysis endpoint, systolic blood pressure. | mmHg | MEAN |
| SECONDARY | Change From Baseline in Systolic Blood Pressure at Week 6 | Baseline and Week 6 | Analysis population includes all participants who received at least 1 dose of study drug and had non-missing change from baseline value at Week 6 for the analysis endpoint, systolic blood pressure. | mmHg | MEAN |
| SECONDARY | Change From Baseline in Diastolic Blood Pressure at Week 2 | Baseline and Week 2 | Analysis population includes all participants who received at least 1 dose of study drug and had non-missing change from baseline value at Week 2 for the analysis endpoint, diastolic blood pressure. | mmHg | MEAN |
| SECONDARY | Change From Baseline in Diastolic Blood Pressure at Week 4 | Baseline and Week 4 | Analysis population includes all participants who received at least 1 dose of study drug and had non-missing change from baseline value at Week 4 for the analysis endpoint, diastolic blood pressure. | mmHg | MEAN |
| SECONDARY | Change From Baseline in Diastolic Blood Pressure at Week 6 | Baseline and Week 6 | Analysis population includes all participants who received at least 1 dose of study drug and had non-missing change from baseline value at Week 6 for the analysis endpoint, diastolic blood pressure. | mmHg | MEAN |
| SECONDARY | Change From Baseline in Heart Rate at Week 2 | Baseline and Week 2 | Analysis population includes all participants who received at least 1 dose of study drug and had non-missing change from baseline value at Week 2 for the analysis endpoint, heart rate. | beats/min | MEAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02720081/outcomes